Markets

Momenta Says District of Delaware Invalidates Teva's MS Drug

Dice with pencil on graph paper

Shares of Momenta Pharmaceuticals, Inc.MNTA shot up 25.2% after Mylan N.V. MYL announced that the U.S. District Court for the District of Delaware has issued a decision in favor of the latter pertaining to claims related to Teva Pharmaceutical's TEVA Copaxone 40mg/mL. This news is a positive for Momenta as well, as the company, along with Novartis' NVS generic arm-Sandoz Inc., is looking to get approval for their generic version (Glatopa 40 mg ) of 40-mg thrice-weekly formulation of Copaxone.

The invalidated patents are United States Patent Numbers 8,232,250; 8,399,413; 8,969,302; and 9,155,776, which are owned by Yeda Research & Development Co., Ltd. and licensed to Teva.

Earlier, in Dec 2016, the U.S. Patent and Trademark Office's U.S. Patent Trial and Appeal Board (PTAB) reaffirmed a prior decision that three of these patents ('250, '413 and '302) are unpatentable in its inter partes review (IPR) proceedings initiated by Mylan. In addition, Mylan also challenged the '776 patent in an IPR proceeding. The PTAB is expected to issue its institution ruling on the '776 patent IPR by Apr 2017.

Further, shares of Momenta have performed better than the Zacks categorized Medical-Biomedical and Genetics industry in the past one year with the stock gaining 50.1% compared to the industry's decline of 9%.

Coming back to Momenta - the company received a boost with the FDA approval of Glatopa 20 mg/ml (a generic version of Copaxone 20 mg) in Apr 2015. The company has a collaboration and license agreement with Sandoz for Glatopa and Enoxaparin Sodium Injection. The company earned a $10 million milestone from Sandoz upon Glatopa's FDA approval and another $10-million milestone upon the first commercial sale of Glatopa. Momenta is also eligible to receive up to $120 million in milestone payments from Sandoz upon the achievement of certain regulatory, commercial and sales-based milestones for Glatopa. Momenta has recorded $715 million in product revenues as well as regulatory and commercial milestones related to Glatopa and Enoxaparin Sodium Injection until Sep 30, 2016.

On the other hand, Teva is expected to face continued sales erosion for Copaxone due to increased competition. The generic market is highly crowded and Teva faces competition from players like Mylan, Dr. Reddy's Laboratories Limited and Sandoz among others.

Momenta Pharmaceuticals, Inc. Price

Momenta Pharmaceuticals, Inc. Price | Momenta Pharmaceuticals, Inc. Quote

Zacks Rank & Key Picks

Momenta currently carries a Zacks Rank #2 (Buy), while Teva carries a Zacks Rank #4 (Sell). You can see the complete list of today's Zacks #1 (Strong Buy) Rank stocks here .

Zacks' Top 10 Stocks for 2017

In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?

Who wouldn't? As of early December, the 2016 Top 10 produced 5 double-digit winners including oil and natural gas giant Pioneer Natural Resources which racked up a stellar +50% gain. The new list is painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. Be among the very first to see it>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Novartis AG (NVS): Free Stock Analysis Report

Momenta Pharmaceuticals, Inc. (MNTA): Free Stock Analysis Report

Teva Pharmaceutical Industries Limited (TEVA): Free Stock Analysis Report

Mylan N.V. (MYL): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

TEVA NVS

Other Topics

Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More